CTIS2022-501363-40-00招募中1 期
NAV-1003
avire Pharma Inc.0 个研究点目标入组 110 人开始时间: 2022年9月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
进行中（未招募）
1 期
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)CTIS2023-506975-83-00Aprogen Inc.720
招募中
1 期
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimabhead and neck squamous cell carcinoma, non-small cell lung cancer or, melanomaCTIS2024-514034-20-00Boehringer Ingelheim International GmbH13
进行中（未招募）
1 期
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of VNA-318 in healthy male subjectsCognitive impairmentMedDRA version: 21.1Level: LLTClassification code: 10009846Term: Cognitive impairment Class: 10029205CTIS2024-512106-26-00Vandria SA96
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100